Ganoderic acid A

Catalog No. BCN3033
CAS RN 81907-62-2
Molecular Weight 516.7
Molecular Formula C30H44O7
Database [PubChem]:382165147
[ChEBI]:
[PCIDB]:23820

Definition

Standard InChI

InChI=1S/C30H44O7/c1-15(10-17(31)11-16(2)26(36)37)18-12-23(35)30(7)25-19(32)13-21-27(3,4)22(34)8-9-28(21,5)24(25)20(33)14-29(18,30)6/h15-16,18-19,21,23,32,35H,8-14H2,1-7H3,(H,36,37)/t15-,16-,18-,19+,21+,23+,28+,29-,30+/m1/s1

Biological Activity

Ganoderic acid A is a lanostane triterpene isolated from Ganoderma lucidum. It exhibits antitumor activity, which is mainly mediated through its inhibitory effect on nuclear transcription factor-kappaB and activator protein-1, it promotes cisplatin-induced cell death by enhancing the sensitivity of HepG2 cells to cisplatin mainly via the signal transducer and activator of transcription 3 suppression. [1]
Ganoderic acid A induces a remarkable cytotoxicity in various leukemia and lymphoma cell lines and primary tumors, with a minor toxicity to nonmalignant B-cells, can upregulate pro-apoptotic protein Bax proteins while downregulating anti-apototic proteins Bcl-2 and survivin, it may play dual roles in inducing apoptosis and enhancing HLA class II Ag presentation, and could be used as novel adjunctive therapy for the treatment of hematological malignancies.[2]
Ganoderic acid A can induce proliferation inhibition, apoptosis and suppression of invasion in human osteosarcoma HOS and MG-63 cells, down-regulate the expression level of phosphorylated STAT3 and increase the phosphorylation level of p38 and NF-κB1 expression in both cells. [3]

Product information

English website: Ganoderic acid A
Japanese website: Ganoderic acid A
Chinese website: Ganoderic acid A

References

[1] Yao X, Li G, Xu H, et al. Planta Medica, 2012, 78(16):1740-8.
[2] Haque A, Radwan F F Y, Hossain A, et al. Cancer Res, 2012, 72(8 Supplement):5641.
[3] Shao J, Li Z, Jiao G, et al. Journal of Southern Medical University, 2015, 35(5):619-24.
[4] Duan-Ping L U, Chen S, Wang Y, et al. Modern Chinese Medicine, 2013, 15(06):496-9.